VYGR News

A bad start to the year only got worse this week as the S&P 500 fell another 2%. For the first time since October, the ninety-day returns swung negative to -0.6%. Just two weeks ago, that number stood at 17%. The VIX is up 48% year-to-date, closing Friday at 27. After 12 companies submitted their initial filings with the SEC in the first week of the year, just three...read more

As we noted in a mid-week blog post, AAAP had the best first-day pop (+53%) for an IPO in three months, and on the same day Voyager had the best pop in almost two months (+27%). While there were no biotech filings this past week, it is a safe...read more

Three biotechs and one regional bank priced and began trading on Wednesday. None broke issue. Only one of the four priced below the range, compared to 85% of IPOs that began trading in October. Advanced Accelerator Applications (AAAP) popped 53%, giving it the best first-day performance for an IPO in the past three months. The diagnostics/therapeutics...read more

Voyager Therapeutics, a gene therapy biotech targeting Parkinson's disease and other CNS disorders, raised $70 million by offering 5.0 million shares at $14, below the range of $15 to $17. It had originally planned to offer 4.69 million shares. Voyager Therapeutics plans to list on the Nasdaq under the symbol VYGR. Cowen & Company and Piper Jaffray acted as lead managers on...read more